Company Profile
Bionomics is a clinical-stage biopharmaceutical company developing innovative therapeutics for central nervous system (CNS) disorders, including anxiety, PTSD, and depression.
Bionomics’ lead candidate, BNC210, is a novel, oral small molecule targeting the α7 nicotinic acetylcholine receptor, designed to reduce anxiety without the side effects associated with benzodiazepines. It is being evaluated in large-scale clinical trials for anxiety and PTSD.
